scholarly journals METASTATIC EYE CANCER AS A PROGNOSTIC FACTOR FOR PATIENT SURVIVAL: A REVIEW ARTICLE

2021 ◽  
Vol 60 (3) ◽  
pp. 48-55
Author(s):  
Milana Ristić ◽  
Sonja Cekić ◽  
Nevena Zlatanović
Keyword(s):  
Prognostic Factor ◽  
Patient Survival ◽  
Review Article

scholarly journals Nonalcoholic steatohepatitis in posttransplantation liver: Review article

2018 ◽  
Vol 64 (2) ◽  
pp. 187-194 ◽  
Author(s):  
Antônio Ricardo Cardia Ferraz de Andrade ◽  
Helma P. Cotrim ◽  
Paulo L. Bittencourt ◽  
Carolina G. Almeida ◽  
Ney Christian Amaral Boa Sorte
Keyword(s):  
Nonalcoholic Steatohepatitis ◽  
Clinical Characteristics ◽  
Metabolic Disorders ◽  
Patient Survival ◽  
De Novo ◽  
Review Article ◽  
Liver Transplants ◽  
The Third ◽  
High Prevalence ◽  
The World

Summary Introduction: Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and occurs as both recurrent and de novo manifestations. De novo NASH can also occur in allografts of patients transplanted for non-NASH liver disease. Objective: To evaluate recurrent or de novo NASH in post-LT patients. Method: A literature review was performed using search engines of indexed scientific material, including Medline (by PubMed), Scielo and Lilacs, to identify articles published in Portuguese and English until August 2016. Eligible studies included: place and year of publication, prevalence, clinical characteristics, risk factors and survival. Results: A total of 110 articles were identified and 63 were selected. Most of the studies evaluated recurrence and survival after LT. Survival reached 90-100% in 1 year and 52-100% in 5 years. Recurrence of NAFLD (steatosis) was described in 15-100% and NASH, in 4-71%. NAFLD and de novo NASH were observed in 18-67% and 3-17%, respectively. Metabolic syndrome, diabetes mellitus, dyslipidemia and hypertension were seen in 45-58%, 18-59%, 25-66% and 52-82%, respectively. Conclusion: After liver transplants, patients present a high prevalence of recurrent and de novo NASH. They also show a high frequence of metabolic disorders. Nevertheless, these alterations seem not to influence patient survival.

scholarly journals Netrin-1 Expression Is an Independent Prognostic Factor for Poor Patient Survival in Brain Metastases

PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e92311 ◽  
Author(s):  
Patrick N. Harter ◽  
Jenny Zinke ◽  
Alexander Scholz ◽  
Julia Tichy ◽  
Cornelia Zachskorn ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Brain Metastases ◽  
Patient Survival ◽  
Independent Prognostic Factor ◽  
Poor Patient ◽  
Poor Patient Survival

scholarly journals CHARACTERISTICS OF THE IMMUNE MICROENVIRONMENT OF THE NORMAL MUCOUS MEMBRANE OF THE PERITUMORAL AREA IS AN ADDITIONAL INDEPENDENT PROGNOSTIC FACTOR IN GASTRIC CANCER

2021 ◽  
Vol 20 (1) ◽  
pp. 74-86
Author(s):  
N. V. Danilova ◽  
V. M. Kkomyakov ◽  
A. V. Chayka ◽  
I. A. Mikhailov ◽  
N. A. Oleynikova ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Mucous Membrane ◽  
Patient Survival ◽  
Lymphocyte Infiltration ◽  
Immune Microenvironment ◽  
Average Area ◽  
Negative Prognostic Factor ◽  
Normal Mucous Membrane ◽  
Analysis System

The aim of the study was to study and evaluate the predictive value of the immune microenvironment of gastric cancer and morphologically normal mucous membrane of the peritumoral area using an automatic morphometric analysis system on the example of CD 8+ cells.Material and Methods. Surgical samples from 130 patients with a verified diagnosis of gastric cancer were used. After immunohistochemical staining with antibodies to CD 8, a morphological assessment was performed according to the original method. We assessed the average area of CD 8+ cells in three fields of view (lens magn. ×20) using the automatic system of morphometric analysis LAS X (Leica) in the central part of the tumor and areas of morphologically normal mucous membrane of the peritumoral region directly adjacent to the tumor tissue. The results were compared with the main clinical and morphological characteristics of the tumor as well as with the overall five-year survival of patients.Results and Discussion. A high density of CD 8+ infiltration of normal mucous membrane of the peritumoral area was observed in groups T4a and T4b by the depth of invasion (n=96, p=0.0089) and was associated with the presence of emboli in the lymphatic vessels (n=96, p=0.0102) and with the more advanced stage of gastric cancer (n=96, p=0.0107). The studied cases were divided into two groups: less than 3300 square micrometers (better patient survival; n=79, p=0.01) and more than 3300 square micrometers according to the average area of CD 8+ cells in normal mucous membrane of the peritumoral area. According to multivariate survival analysis using the Cox regression model, it was found that the average area of CD 8+ cells in normal mucous membrane of the peritumoral area was a significant negative prognostic factor (RR=1.537; CI : 0.761–3.105; p<0.01) comparable in degree covariance with the stage of the tumor A similar indicator assessed in central part of the tumor was not significantly associated with patient survival (RR=0.803; CI : 0.574–1.122; p>0.05).Conclusion. The possibility of using an automatic analysis system to evaluate the immune microenvironment in gastric cancer was demonstrated for the first time. It was found that a high level of CD 8+ lymphocyte infiltration of morphologically normal mucous membrane of the peritumoral area was an independent negative prognostic factor. Therefore, we recommend the mandatory preoperative biopsy sampling from the mucous membrane of the peritumoral region for morphometric assessment of CD 8+ lymphocyte infiltration. 

scholarly journals Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5336-5336
Author(s):  
Huimin Liu ◽  
Wenjie Xiong ◽  
Heng Li ◽  
Rui Lv ◽  
Wei Liu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Platelet Count ◽  
Survival Rate ◽  
Prognostic Factor ◽  
Patient Survival ◽  
Elevated Serum ◽  
Progression Free Survival ◽  
Albumin Level ◽  
Lymphoproliferative Disorders ◽  
Free Survival

Abstract Background: B-cell chronic lymphoproliferative disorders (B-CLPD) comprise several indolent lymphoma subtypes with similar characteristics but also difference and heterogeneity. Several prognostic systems had been established for separate subtypes, such as Rai/Binet stage system for CLL, FLIPI for follicular lymphoma. Here, we want to explore the prognostic role of some common clinical characteristics in each lymphoma subtype, such as serum LDH. Materials and methods: The clinical data of 829 patients with B-CLPD including clinical features, LDH expression level, cytogenetic abnormalities and therapeutic outcome were analyzed retrospectively in department of lymphoma & myeloma, Institute of hematology & Blood disease hospital from April 1990 to August 2013, and the prognosis of B-CLPD patients with different expression levels of LDH was compared, including overall survival (OS) and progression-free survival (PFS) rates. Results: 829 patients were divided into three groups, including 426 (51.4%) patients with chronic lymphocytic lymphoma (CLL), 307 (37.0%) patients with non-CLL B-CLPD and 96 (11.6%) patients with BLPD-U. Elevated serum LDH at diagnosis was detected in 112 (26.3%), 85 (27.7%) and 23 (24.9%) of CLL, non-CLL B-CLPD and BLPD-U group, respectively. Patients with elevated LDH B-CLPD had poorer 5-year overall survival rate (CLL: 63.8% vs 83.0%; non-CLL B-CLPD: 62.2% vs 78.1%; BLPD-U: 47.4% vs 88.6%) and 5-year progression-free survival rate (CLL: 52.0% vs 78.2%; non-CLL B-CLPD: 40.8% vs 75.6%; BLPD-U: 48.9% vs 89.5%) than LDH normal patients. Univariate analysis showed that LDH expression, hemoglobin level, platelet count, B symptoms, P53 deletion were prognostic factors for CLL patient survival, while LDH expression, platelet count, albumin level affected non-CLL B-CLPD patient survival significantly and LDH expression, albumin level, ECOG PS scores for BLPD-U patient survival. Multivariate analysis showed that elevated LDH was an independent significant prognostic factor for overall survival (P<.001) and progression-free survival (P<.001) in all three groups. Conclusion s: Based on these data, we conclude that elevated serum LDH at diagnosis is an unfavorable prognostic factor in patients with B-CLPD. Disclosures No relevant conflicts of interest to declare.

Overcoming the challenges in the treatment of glioblastoma via nanocarrier based drug delivery approach

2021 ◽  
Vol 27 ◽  
Author(s):  
Saurabh Mittal ◽  
Javed Ali ◽  
Sanjula Baboota
Keyword(s):  
Drug Delivery ◽  
Patient Survival ◽  
Review Article ◽  
Adult Brain ◽  
Brain Delivery ◽  
Drug Solubility ◽  
High Grade Astrocytoma ◽  
Near Future ◽  
Delivery Approach ◽  
Patient Survival Rate

Background: Glioblastoma multiforme is the most malignant form of high-grade astrocytoma. Clinically it is characterized as 4thgrade of astrocytoma having necrotic tissue and hyperplastic blood vessel. It is observed to be the most frequent adult brain tumor representing an overall 15.4% of all brain tumors and about 60-75% of the entire astrocytoma. There are limited therapies available and the most widely used therapy includes surgical intrusion followed by radiotherapy plus chemotherapy (paclitaxel, temozolomide, docetaxel, etc); with an overall patient survival rate from 6–14 months. Various studies have proved that nanoformulations offer considerable advantages like enhanced drug solubility, targeted activity, and attenuated side effects. Objective: The key objective of this review article is to exemplify numerous studies carried out using nanocarriers for overcoming the challenges associated with the treatment of glioblastoma. It also describes the pathways associated with the induction, initiation, and progression of glioblastoma. Methods: Research articles that focused on the use of nanocarrier-based drug delivery approach for the treatment of various glioblastoma were collected from different search engines, such as Google Scholar, Science Direct, and PubMed using keywords like glioblastoma, nanocarriers, Brain delivery, etc. Results: Nanocarriers have shown enormous potential in overcoming the challenges associated with the treatment of glioblastoma. Conclusion: Broad research is still needed so that these nanocarriers can be used clinically for the welfare of mankind, in the management of glioblastoma, in near future.

Expression of receptors for estrogen and progesterone in malignant colonic mucosa as a prognostic factor for patient survival

1999 ◽  
Vol 72 (4) ◽  
pp. 225-229 ◽  
Author(s):  
Ioannis G. Kaklamanos ◽  
Oliver F. Bathe ◽  
Dido Franceschi ◽  
Andreas Ch. Lazaris ◽  
Panagiotis Davaris ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Colonic Mucosa ◽  
Patient Survival

Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry

2019 ◽  
Author(s):  
Maxime Courant ◽  
Sebastien Orazio ◽  
Alain Monnereau ◽  
Julie Preterre ◽  
Christian Combe ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Factor ◽  
Renal Impairment ◽  
Clinical Outcomes ◽  
Excess Mortality ◽  
Patient Survival ◽  
Population Based ◽  
Renal Response ◽  
Factors Associated ◽  
Population Based Registry

Abstract Background Renal impairment (RI), a severe complication in multiple myeloma (MM), is considered as a poor prognostic factor. Patient survival has increased with the use of novel drugs and autologous stem-cell transplantation (ASCT). However, specific evolution of the incidence of RI in MM and its impact on prognosis remain unclear. Methods Using a population-based registry of 1038 newly diagnosed MM in Gironde, France, we evaluated the incidence trends of RI in MM patients and assessed net survival according to factors of interest using Pohar-Perme indicator and excess mortality rate regression. We also reviewed 114 cases of MM with RI to describe their clinical outcomes. Results In our population-based study, 24.6% of MM patients presented with RI (12.9% required haemodialysis). Median survival time was 21 months in patients with RI versus not reached at 3 years for other patients (P < 0.01). Age >73 years, RI, comorbidities and non-use of drugs or ASCT were associated with excess mortality risk. The effect of RI on excess mortality rates was maximum in the first 6 months after diagnosis. In the observational study, median follow-up time was 22.5 months; factors associated with renal response were haematologic response [odds ratio (OR) 6.81; P < 0.01] and previous chronic kidney disease (OR 0.26; P = 0.04). Factors associated with 1-year overall survival were haematological [hazard ratio (HR) 0.13; P < 0.01] and renal response (HR 0.27; P = 0.03). Conclusions RI represents an independent negative prognostic factor in MM in the first 6 months after diagnosis. Renal recovery and haematologic response are the strongest markers associated with patient survival.

scholarly journals Thrombocytopenia in solid tumors: Prognostic significance

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Majid Ghanavat ◽  
Mina Ebrahimi ◽  
Hassan Rafieemehr ◽  
Mahmood Maniati ◽  
Masumeh Maleki Behzad ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Solid Tumors ◽  
Prognostic Significance ◽  
Therapeutic Strategies ◽  
Review Article ◽  
Bleeding Complications ◽  
Bleeding Disorders ◽  
Common Complication ◽  
Poor Prognostic Factor ◽  
Underlying Mechanisms

Solid tumors are a heterogeneous group of malignancies that result from out-of-control proliferation of cells. Thrombocytopenia is a common complication among patients with solid tumors that predispose them to bleeding disorders. The aim of this review article is to investigate the underlying mechanisms of the risk and incidence of thrombocytopenia in solid tumors. It can be argued that thrombocytopenia is a poor prognostic factor in solid tumors that can result from several factors such as polymorphism and mutation in some transcription factors and cytokines involved in megakaryocytic maturation or from the adverse effects of treatment. Therefore, an understanding of the exact mechanism of thrombocytopenia pathogenesis in each stage of solid tumors can help in developing therapeutic strategies to decrease bleeding complications in these malignancies.

Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.

1985 ◽  
Vol 3 (11) ◽  
pp. 1503-1507 ◽  
Author(s):  
M Boccadoro ◽  
A Gallamini ◽  
A Fruttero ◽  
P Gavarotti ◽  
V Redoglia ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Acid Phosphatase ◽  
Prognostic Factor ◽  
Plasma Cell ◽  
Patient Survival ◽  
Labeling Index ◽  
Survival Duration ◽  
Monoclonal Gammopathies ◽  
Thymidine Labeling Index ◽  
Cell Acid

Plasma cell acid phosphatase (AP) activity and thymidine labeling index (LI%) were evaluated concomitantly in 52 patients with monoclonal gammopathies. AP score, percentage of AP positive plasma cells, and LI% were significantly higher in 26 patients with multiple myeloma (MM) at the time of diagnosis than in 11 monoclonal gammopathy of undetermined significance (MGUS) and eight smoldering myeloma (SM) patients. LI% had the highest statistical correlation with disease status. A 1% cutoff could clearly separate the patients with progressive MM compared to those with stable disease (SM-MGUS) (P less than .001). There was a significant overall correlation between the AP score and LI% (P less than .005). Since LI% is a recognized powerful prognostic factor, this correlation suggests that the AP score can also be a reliable test predicting patient survival duration. In addition, we identified a subgroup of IgG MM patients with very high tumor mass who had a low LI% but a high AP score. This was associated with very poor patient survival and indicated the discrete prognostic importance of AP score in this subgroup with low LI%. Thus, both the LI% and AP score can be recommended as helpful clinical tests in patients with monoclonal gammopathies.

Sign in / Sign up

Export Citation Format

Share Document